1 Cannabis Stock That’s My Speculative Sector Play

The cannabis boom has come and gone, but this cannabis stock may still have a chance to rise higher.

| More on:
Medicinal research is conducted on cannabis.

Source: Getty Images

Cannabis stocks have had a wild ride over the past few years. First came the hype, then the crash, and more recently, a period of stagnation as companies struggled with oversupply, regulatory hurdles, and slow profitability. It’s no wonder most investors have written the sector off entirely. But sometimes, when a stock is down and out, that’s exactly when it starts to get interesting. For me, Canopy Growth (TSX:WEED) is one cannabis stock that still earns a place in a speculative corner of my portfolio.

Don’t dive in

Let’s be clear: Canopy is not a stock for the faint of heart. It has lost nearly all of its value from the peak in 2018 and continues to face mounting losses. But lately, there are some green shoots, pun intended, that suggest a turnaround may finally be taking root. The cannabis stock’s fourth quarter fiscal 2025 results showed progress on its cost-cutting efforts and a renewed focus on its core markets.

Revenue came in at $65 million, slightly down 11% from the year before, but what stood out was the narrowing of losses. The company identified and will deliver at least $20 million in annualized savings over the next year and a half, if not sooner. There’s still a big red number, but it’s a massive improvement. The cannabis stock has been restructuring aggressively, exiting unprofitable markets, shutting down inefficient operations, and leaning into its BioSteel sale to free up cash.

Even more interesting is Canopy’s U.S. strategy. Through its holding company, Canopy USA, it plans to consolidate its American cannabis assets, including Acreage Holdings and Jetty Extracts. This could eventually give it an early lead if and when U.S. federal legalization moves forward. That’s still a big “if,” of course, but the upside is enormous if the political winds shift.

Considerations

Still, it’s not all sunshine. Canopy remains in a fragile position, and dilution is always a risk as it continues raising funds. The cannabis market is still very competitive, and Canopy has lost market share in the past. But the cannabis stock now has a clearer plan than it has had in years. It’s focusing on premium products, like its Tweed and 7ACRES brands, and is working to simplify its business model. If management can keep improving margins and trimming the fat, it may finally have a fighting chance.

Right now, shares trade for around $1.64, a far cry from the $60-plus levels we saw back in the mania days. At this level, the cannabis stock is being priced as if it’s going out of business. That creates a very asymmetric risk-reward setup. If Canopy manages to survive and tap into U.S. growth, there’s room for a substantial rebound. If it doesn’t, the downside from here is much smaller than it was five years ago.

Another reason I’ve added Canopy to my speculative watchlist is sentiment. Most investors have long since moved on, and many institutions avoid cannabis entirely due to federal regulations. That leaves a vacuum. If there’s even a whiff of regulatory change or a positive earnings surprise, it could spark a major short-term rally.

Bottom line

Of course, this is not the kind of cannabis stock to bet the farm on. It’s more like a lottery ticket with a slightly better chance of paying off. But in every portfolio, I think there’s room for a high-risk, high-reward play, so long as you know the risks going in.

Cannabis still has long-term potential. Legalization trends are progressing globally, and Canada continues to be a testing ground for what’s to come. Canopy isn’t the dominant player it once was, but it’s showing signs of life. With improving financials, strategic realignment, and optionality in the U.S., it’s one cannabis stock that has just enough spark left to make it worth the risk.

Fool contributor Amy Legate-Wolfe has positions in Canopy Growth. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

More on Cannabis Stocks

four people hold happy emoji masks
Dividend Stocks

Wary of Mining Companies? A Lower-Risk Way to Get in on the Gold and Silver Surge

Frenco-Nevada (TSX:FNV) stock might be a wiser way to play the run in gold prices this year.

Read more »

Cannabis smoke
Cannabis Stocks

Have Cannabis Stocks Totally Gone Up in Smoke?

Let's dive into whether Canadian cannabis stocks are still investable, and what investors should make of the recent volatility in…

Read more »

Researcher works in hemp field
Cannabis Stocks

1 Undervalued Cannabis Stock to Buy and Hold Over the Next Decade

Green Thumb is a beaten-down cannabis stock that trades at a compelling valuation in September 2025.

Read more »

Researcher works in hemp field
Cannabis Stocks

Pot Stocks Rallied Hard in August: Is There More to Come?

Tilray Brands (TSX:TLRY) and the broad basket of pot stocks could heat up from here.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Canopy Growth Stock Jumped 30% Last Month: What’s Going on?

Canopy Growth (TSX:WEED) stock is picking up traction again, making it an enticing weed play to buy on strength.

Read more »

A cannabis plant grows.
Cannabis Stocks

These Threats Facing Canopy Growth Stock Could Justify Selling it

Let's dive into whether Canopy Growth (TSX:WEED) is a top stock investors should buy right now after its recent dip…

Read more »

A person holds a small glass jar of marijuana.
Stocks for Beginners

This BioCannabis Firm Could Explode with Product Approval

This cannabis stock used to be a major name, so where does it stand now?

Read more »

Medicinal research is conducted on cannabis.
Stocks for Beginners

This TSX Health-Care Stock Is a Long-Term Buy for Patient Investors

This TSX stock continues to be one of the best long-term opportunities, if you're patient.

Read more »